Search Results 1471-1480 of 18666 for Appendix

1. Study of Sacituzumab Govitecan (IMMU-132) in Metastatic or Locally Advanced Unresectable Urothelial Cancer - Mayo Clinic

   ... Appendix 6. Exclusion Criteria: Women who are pregnant or lactating. z; Have had a prior anti-cancer mAb/ADC within 4 weeks prior to C1D1 or have had prior ...

2. A Study to Evaluate Treatment of Established Chemotherapy-induced Neuropathy with Fingolimod - Mayo Clinic

   ... Appendix VI). ECOG Performance Status (PS) 0, 1 or 2. Negative pregnancy test done ≤ 14 days prior to registration, for persons of childbearing potential ...

3. Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) - Mayo Clinic

   Have a Karnofsky Performance Scale (KPS) (Appendix 11.8) score (for subjects ≥16 years of age) or Lansky Play Performance Scale (LPPS) (Appendix 11.7) ...

4. Simulated Teleneonatology Consult - Mayo Clinic

   An error occurred, please try again later. Copy for customer care: session ID undefined. Try again. Share · Tweet . VID-20442919.

5. Paget's disease of the breast - Doctors and departments - Mayo Clinic

   This rare form of breast cancer causes breast skin changes. Learn about the symptoms, causes, diagnosis and treatments, including surgery.

6. Colectomy - Doctors & Departments - Mayo Clinic

   11, 2025. Related. Appendix cancer · Clear liquid diet · Colon cancer · Colon polyps · Colostomy · Crohn's disease · Diverticulitis · Familial adenomatous ...

7. Inflammatory bowel disease (IBD) - Symptoms and causes - Mayo Clinic

   Ulcerative colitis. This condition involves inflammation and sores, called ulcers, along the lining of the colon and rectum. · Crohn's disease. In this type of ...

8. Study of TERN-601 in Adults with Overweight or Obesity - Mayo Clinic

   2. Male and/or female, must be willing to follow the contraception requirements defined by the study protocol (Appendix 10). Female participants of ...

9. Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed By Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance In Treatment-Naïve Mantle Cell Lymphoma - Mayo Clinic

   Disease should be FDG-avid based on PET. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. (Appendix A); Age ≥ 18 years and considered a ...

10. Publications - Harish Ramakrishna, M.D. - Mayo Clinic

    ... Appendix). Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID ...